INSTITUTO DE BIOMEDICINA Y GENÉTICA MOLECULAR (IBGM)
Instituto
Cleveland Clinic
Cleveland, Estados UnidosPublicaciones en colaboración con investigadores/as de Cleveland Clinic (10)
2024
-
Anticoagulation Use and Endovascular Thrombectomy in Patients with Large Core Stroke: A Secondary Analysis of the SELECT2 Trial
Annals of Neurology, Vol. 96, Núm. 5, pp. 887-894
-
Association of Reperfusion and Procedural Characteristics with Endovascular Thrombectomy Outcomes in Large Core Stroke: Sub-Analysis from the SELECT2 Trial
Annals of Neurology
-
Clinical relevance of intracranial hemorrhage after thrombectomy versus medical management for large core infarct: a secondary analysis of the SELECT2 randomized trial
Journal of NeuroInterventional Surgery, pp. 1-8
-
Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients with Large Ischemic Strokes: A Prespecified Analysis of the SELECT2 Trial
JAMA Neurology, Vol. 81, Núm. 4, pp. 327-335
-
Endovascular Thrombectomy for Large Ischemic Stroke Across Ischemic Injury and Penumbra Profiles
JAMA, Vol. 331, Núm. 9, pp. 750-763
-
Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial
The Lancet, Vol. 403, Núm. 10428, pp. 731-740
2023
-
Association of Endovascular Thrombectomy vs Medical Management with Functional and Safety Outcomes in Patients Treated beyond 24 Hours of Last Known Well: The SELECT Late Study
JAMA Neurology, Vol. 80, Núm. 2, pp. 172-182
2021
-
SELECTion criteria for large core trials: Dogma or data?
Journal of NeuroInterventional Surgery
2016
2004
-
The retinoid antagonist MX781 induces clusterin expression in prostate cancer cells via heat shock factor-1 and activator protein-1 transcription factors
Cancer Research, Vol. 64, Núm. 16, pp. 5905-5912